Davis Elizabeth Mahoney
Department of Otolaryngology-Head and Neck Surgery, Boston University School of Medicine, 830 Harrison Avenue, Suite 1400, Boston, MA 02118 USA.
Curr Otorhinolaryngol Rep. 2022;10(2):167-171. doi: 10.1007/s40136-022-00393-7. Epub 2022 Mar 9.
To summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic.
At the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that the major factor in dose adjustment is the time elapsed from the last dose.
Resuming outpatient allergy services in the setting of the COVID-19 pandemic poses many challenges to the practitioner. Allergy specialists are now faced with developing prudent and evidence-based strategies for safely resuming allergen immunotherapy, while also maintaining a safe environment for staff and patients.
总结并回顾近期关于变应原免疫疗法在全球大流行背景下作用的文献。
在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行开始时，包括变应原免疫疗法在内的大多数非紧急门诊患者护理服务都暂停了。现在随着医疗业务重新开放，过敏症专科医生必须制定恢复过敏患者护理的计划和方案，包括重新启动变应原免疫疗法的策略。虽然目前尚无已发表的基于证据的恢复变应原免疫疗法的方案，但有限的科学数据和专家意见表明，剂量调整的主要因素是距上次给药的时间。
在2019冠状病毒病（COVID-19）大流行背景下恢复门诊过敏服务给从业者带来了诸多挑战。过敏症专科医生现在面临着制定谨慎且基于证据的策略以安全恢复变应原免疫疗法，同时还要为工作人员和患者维持一个安全的环境。
